Kintor Pharma Gets Mega-Booster from Experimental Covid-19 Drug

Company posted major milestone last week with the first emergency use authorization for its drug Proxalutamide to treat the coronavirus in Paraguay Key points:  Kintor Pharma’s Proxalutamide could become a blockbuster drug if it receives emergency use approval in the U.S. as a treatment for Covid-19 The company’s stock has jumped sevenfold this year, outpacing even the most bullish analyst targets By Alice Leung It’s relatively rare to see a stock trade higher than analysts’ targets, since such people tend to be quite bullish on the companies they follow. But…

Read MORE »

Drug Maker I-Mab Wins Plaudits as Analysts Urge Caution on Soaring Stock

Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members Key points: I-Mab’s shares have nearly doubled over the past six months on major licensing deal, fundraising and pending drug approvals Appointment of two new well-connected board members could expedite first approvals of company’s drugs in China By Richard Barbarossa Cancer drug developer I-Mab (IMAB.US) has been on a roll this year. The company’s shares have nearly doubled in the past six months after it recorded its…

Read MORE »